Irritable Bowel Syndrome--diarrhoea
Overview
Authors
Affiliations
IBS is a functional gastrointestinal disorder which has been subtyped according to bowel habits. This review presents recommendations for IBS-D which makes up about 1/3 of all patients and which is defined as IBS with loose or watery stools with ≥25% of bowel movements. Because IBS is a complex biopsychosocial illness, treatment cannot and should not be directed only to altered bowel habits. Evidence will be presented for dietary manipulations, probiotics and pharmacotherapies including tricyclic agents, antibiotics, serotonin antagonists and anti-diarrhoeal agents in the management of patients with IBS-D.
Bordbar G, Miri M, Omidi M, Shoja S, Akhavan M Gastroenterol Res Pract. 2020; 2020:8213082.
PMID: 32565786 PMC: 7273440. DOI: 10.1155/2020/8213082.
Mohebbi Z, Sharif F, Peyrovi H, Rakhshan M, Alizade Naini M, Zarshenas L Electron Physician. 2018; 9(12):5885-5893.
PMID: 29560138 PMC: 5843412. DOI: 10.19082/5885.
Irritable bowel syndrome: a microbiome-gut-brain axis disorder?.
Kennedy P, Cryan J, Dinan T, Clarke G World J Gastroenterol. 2014; 20(39):14105-25.
PMID: 25339800 PMC: 4202342. DOI: 10.3748/wjg.v20.i39.14105.
Planar bioadhesive microdevices: a new technology for oral drug delivery.
Fox C, Chirra H, Desai T Curr Pharm Biotechnol. 2014; 15(7):673-83.
PMID: 25219863 PMC: 4227534. DOI: 10.2174/1389201015666140915152706.
Minireview: Gut microbiota: the neglected endocrine organ.
Clarke G, Stilling R, Kennedy P, Stanton C, Cryan J, Dinan T Mol Endocrinol. 2014; 28(8):1221-38.
PMID: 24892638 PMC: 5414803. DOI: 10.1210/me.2014-1108.